Product InformationNaltrexone- a unique immune regulator showing promise in all manner of autoimmune diseases including HIV
Over recent years there has been a growing recognition that autoimmune diseases result from immunodeficiency, specifically a disturbance of the ability of the immune system to distinguish its "self" from "non-self".
The experiences of individuals with autoimmune diseases who have begun a regime of low dose treatment with naltrexone have been remarkable. Patients with diagnoses as diverse HIV, lupus, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, ALS (Amyotrophic Lateral Sclerosis) and Crohn's disease have all benefited.
In addition, people with fibromyalgia and chronic fatigue syndrome have had marked improvement using low dose naltrexone, suggesting that these conditions also have an autoimmune issue as well.
Naltrexone was originally approved in 1984 to help addicts come off opioids and heroin by blocking the receptors in the brain that trigger the affects of these narcotics. To this end naltrexone is usually available in dosages of 50mg tablets to assist persons wishing to “kick their habits.”
However more recently it has become apparent that a low dose of naltrexone (3mg to 5mg) has a significant effect in normalizing the immune system. For example, the November 13, 2003 issue of the New England Journal of Medicine stated: "Opioid-Induced Immune Modulation: the preclinical evidence indicates overwhelmingly that opioids alter the development, differentiation, and function of immune cells, and that both innate and adaptive systems are affected. Bone marrow progenitor cells, macrophages, natural killer cells, immature thymocytes and T cells and B cells are all involved. The relatively recent identification of opioid-related receptors on immune cells makes it even more likely that opioids have direct effects on the immune system."
With this in mind naltrexone has been used by a number of leading physicians to assist their patients with numerous disorders that are essentially of an autoimmune nature.
354 patients with cancer have been treated by leading naltrexone supporter- Dr. Bernard Bihari. Over a 6-monht period 86 have shown objective signs of significant tumor shrinkage and 75% have shown tumor reduction. Of the total, 125 patients have stabilized and are moving toward remission.
Research by others on various human tumors, has found opioid receptors in many types of cancer, including: brain tumors, breast cancers, endometrial cancer, head and neck squamous cell carcinoma, myeloid leukemia, lung cancer and neuroblastoma.
In May 2006, clinical trial researchers at Pennsylvania State University College of Medicine reported: "LDN therapy offers an alternative, safe, effective, and economic means of treating subjects with active Crohn's disease."
It has been noted that patients with autoimmune disease such as ALS (Lou Gehrig's Disease), Alzheimer's Disease, Autism Spectrum Disorders, Chronic Fatigue Syndrome, Emphysema, Endometriosis, Fibromyalgia, HIV/AIDS, Irritable Bowel Syndrome, Multiple Sclerosis, Parkinson's Disease, Primary Lateral Sclerosis, Rheumatoid Arthritis and Systemic Lupus that none have failed to respond to low doses of naltrexone and that all have experienced a halt in the progression of their disorders. In some patients there is a marked remission in the signs and symptoms. The greatest numbers of patients (some 400) treated by Dr. Birhari are those suffering from multiple sclerosis, yet to date less than 1% of these patients has ever experienced a fresh attack of MS whilst they have maintained their regular low dose naltrexone nightly therapy.
As of September 2003, Dr. Bihari has been treating 350 AIDS patients using low dose naltrexone in conjunction with standard AIDS therapies. In this time more than 85% of these patients have shown no detectable levels of the HIV virus along with no significant side effects.
The regular dose of naltrexone is between 2.5mg and 5mg, taken each night at bedtime; i.e., between 9pm and 3am.
Description: Naltrexone is used in various addictive disorders and is also being used as an adjunct for a number of autoimmunity related problems.
Directions: Take 1 capsule daily.
Disclaimer: This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease.
Serving Size: 1 capsule
Amount Per Serving
% Daily Value * not established
Other ingredients: Avicel in a gelatine capsule.
Note: Keep in cool dark conditions, out of the reach of children and consume before end of expiry date. Not for use by pregnant or lactating women.
Formulated and distributed by Profound Products, PO Box 6, Sark GY9 0SB, Great Britain